WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2022> 28> 4

Volume: 28 Issue: 4

1. Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis Page:876—889
2. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach Page:841—850
3. Non-alcoholic fatty liver disease and risk of dementia: Unmet need for a pooled analysis of cohort studies Page:933—934
4. Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations Page:802—805
5. Forms of cholangitis to be considered after SARS-CoV-2 infection Page:929—930
6. Surveillance for hepatocellular carcinoma: It is time to move forward Page:810—813
7. Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies Page:931—932
8. Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study Page:926—928
9. Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex trait Page:806—809
10. Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases Page:773—789
11. Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus Page:912—925
12. Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis Page:864—875
13. Erratum to ‘History and future of hepatitis B virus control in South Korea’ Clin Mol Hepatol 2021;27:620-622 Page:939—939
14. Personalized medicine in nonalcoholic fatty liver disease Page:935—938
15. Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF- κB signaling pathways Page:827—840
16. The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults Page:814—826
17. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis Page:890—911
18. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease Page:851—863
19. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name Page:790—801
20. Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review Page:739—753
21. Deep learning-based prediction of molecular cancer biomarkers from tissue slides: A new tool for precision oncology Page:754—772
22. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review Page:725—738
23. The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology Page:706—724

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.